Cancer Type/Condition: Leukemia, acute myeloid (AML), adult
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: MK1-192, NCT00180128
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 0 to 75 Sponsor: Other Protocol IDs: LPA 2005, NCT00408278
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 30052004, NCT00196768
|
|
6.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PETHEMA-LAM07, NCT01041040
|
|
7.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LENA-LMA-5, NCT01198054
|
|
8.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EPC2008-02, NCT01347996
|
|
9.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: AML-01.10, NCT01587430
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 61 and over Sponsor: Other Protocol IDs: EORTC-06031, NCT00091234
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 35 and under Sponsor: Other Protocol IDs: 2000LS040, MT2000-12, 0005M52481, UMN-2000LS040, NCT00176839
|
|
12.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
13.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
|
|
15.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MYFLAI07, NCT00909168
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
|
|
17.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1227, NA_00071844, NCT01588951
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: AML_CR2_allo_HSCT, NCT00125606
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: 35 to 55 Sponsor: Other Protocol IDs: P040420, AOM04088, NCT00224614
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: AMLCG 99, BMBF 01 GI 02070, NCT00266136
|
|
22.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 55/05, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 51 to 70 Sponsor: Other Protocol IDs: TRALG1/02, NCT00342316
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P050604, NCT00378365
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
|